Retatrutide

Study 1: Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide

Authors: Wenzhuo Li, Qingtong Zhou, Zhaotong Cong, Qingning Yuan, Wenxin Li, Fenghui Zhao, H. Eric Xu, Li-Hua Zhao, Dehua Yang & Ming-Wei Wang

Scientific Findings

This study utilized cryo-electron microscopy to elucidate the structural basis of Retatrutide’s triple agonism at the GLP-1, GIP, and GCG receptors. The researchers determined the structures of Retatrutide in complex with each of the three receptors, revealing that the peptide adopts a single continuous helix. The triple agonism is achieved through a combination of conserved interactions and receptor-specific contacts within the transmembrane domain. The study identified key residues and structural features, such as the conformation of extracellular loop 1 (ECL1) in GIPR, that contribute to the differential binding and activation of the receptors. Mutagenesis and cAMP signaling assays confirmed the functional importance of these interactions, providing a molecular blueprint for Retatrutide’s potent and balanced activity.

Plain English Interpretation

Scientists have figured out how the new weight-loss drug, Retatrutide, works at a molecular level. This drug is unique because it can activate three different hormone receptors in the body that control appetite and metabolism. Using powerful microscopes, the researchers took detailed 3D pictures of Retatrutide as it was bound to each of these three receptors. They discovered that the drug uses a clever strategy of both sticking to parts that all three receptors have in common and also making specific connections with unique parts of each receptor. This allows it to effectively ‘talk’ to all three at once, leading to its powerful effects on weight loss and blood sugar control. Understanding this mechanism helps to explain why Retatrutide is so effective and can guide the development of even better medicines in the future.